Attilio Orazi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3190390/publications.pdf

Version: 2024-02-01

291 papers	22,925 citations	23500 58 h-index	9073 144 g-index
306 all docs	306 docs citations	306 times ranked	19581 citing authors

#	Article	IF	Citations
1	The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 2016, 127, 2391-2405.	0.6	7,429
2	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood, 2022, 140, 1200-1228.	0.6	814
3	Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood, 2007, 110, 1092-1097.	0.6	808
4	The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nature Genetics, 1997, 16, 161-170.	9.4	753
5	MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 121, 4021-4031.	0.6	596
6	Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. Journal of Clinical Oncology, 2012, 30, 3460-3467.	0.8	590
7	European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica, 2005, 90, 1128-32.	1.7	545
8	The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes. Journal of Thoracic Oncology, 2015, 10, 1383-1395.	0.5	463
9	Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment. Leukemia, 2008, 22, 437-438.	3.3	443
10	The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer Journal, 2018, 8, 15.	2.8	404
11	Hyperleukocytic Leukemias and Leukostasis: A Review of Pathophysiology, Clinical Presentation and Management. Leukemia and Lymphoma, 2000, 39, 1-18.	0.6	311
12	Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood, 2012, 120, 3986-3996.	0.6	301
13	Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia, 2012, 26, 2103-2113.	3.3	301
14	Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leukemia Research, 2007, 31, 737-740.	0.4	288
15	CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood, 2013, 121, 2715-2724.	0.6	206
16	Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma.. Journal of Clinical Oncology, 1990, 8, 768-778.	0.8	204
17	Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood, 2014, 123, 2645-2651.	0.6	192
18	The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia, 2008, 22, 1308-1319.	3.3	170

#	Article	IF	Citations
19	An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. Blood, 2015, 125, 1857-1865.	0.6	153
20	Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget, 2017, 8, 73483-73500.	0.8	153
21	Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica, 2013, 98, 255-263.	1.7	142
22	Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach. Haematologica, 2009, 94, 264-268.	1.7	140
23	Therapeutic leukapheresis in hyperleucocytic leukaemias: lack of correlation between degree of cytoreduction and early mortality rate. British Journal of Haematology, 1997, 98, 433-436.	1.2	135
24	MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood, 2014, 124, 1183-1191.	0.6	135
25	Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinico-pathological entity. British Journal of Haematology, 1991, 78, 161-166.	1.2	132
26	Haemophilus ducreyi Elicits a Cutaneous Infiltrate of CD4 Cells during Experimental Human Infection. Journal of Infectious Diseases, 1996, 173, 394-402.	1.9	130
27	Hematopoietic precursor cells within the yolk sac tumor component are the source of secondary hematopoietic malignancies in patients with mediastinal germ cell tumors. Cancer, 1993, 71, 3873-3881.	2.0	129
28	Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes. Leukemia, 2015, 29, 66-75.	3.3	122
29	Prevalence and Clinical Implications of Epsteinâ€“Barr Virus Infection in De Novo Diffuse Large B-Cell Lymphoma in Western Countries. Clinical Cancer Research, 2014, 20, 2338-2349.	3.2	117
30	Expression of the IRTA1 receptor identifies intraepithelial and subepithelial marginal zone B cells of the mucosa-associated lymphoid tissue (MALT). Blood, 2003, 102, 3684-3692.	0.6	114
31	Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Modern Pathology, 2014, 27, 958-971.	2.9	112
32	Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis. Leukemia and Lymphoma, 2006, 47, 998-1005.	0.6	108
33	Histopathology in the Diagnosis and Classification of Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Myelodysplastic/Myeloproliferative Diseases. Pathobiology, 2007, 74, 97-114.	1.9	108
34	Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. Modern Pathology, 2016, 29, 854-864.	2.9	104
35	Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. Blood, 2013, 122, 1881-1886.	0.6	99
36	An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. Haematologica, 2015, 100, 1117-1130.	1.7	97

#	Article	IF	Citations
37	Primary testicular diffuse large B-cell lymphoma belongs to the nongerminal center B-cell-like subgroup: a study of 18 cases. Modern Pathology, 2006, 19, 1521-1527.	2.9	94
38	Chronic myelomonocytic leukemia: the role of bone marrow biopsy immunohistology. Modern Pathology, 2006, 19, 1536-1545.	2.9	93
39	Adrenal Myelolipomas Show Nonrandom X-chromosome Inactivation in Hematopoietic Elements and Fat: Support for a Clonal Origin of Myelolipomas. American Journal of Surgical Pathology, 2006, 30, 838-843.	2.1	93
40	Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. Oncotarget, 2016, 7, 2401-2416.	0.8	93
41	Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. Haematologica, 2019, 104, 1935-1949.	1.7	93
42	Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 4513-4518.	3.3	86
43	Transformation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma to Interdigitating Dendritic Cell Sarcoma. American Journal of Clinical Pathology, 2009, 132, 928-939.	0.4	86
44	Hypoplastic Myelodysplastic Syndromes Can Be Distinguished From Acquired Aplastic Anemia by CD34 and PCNA Immunostaining of Bone Marrow Biopsy Specimens. American Journal of Clinical Pathology, 1997, 107, 268-274.	0.4	84
45	Acute panmyelosis with myelofibrosis: an entity distinct from acute megakaryoblastic leukemia. Modern Pathology, 2005, 18, 603-614.	2.9	84
46	Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up. Haematologica, 2014, 99, 937-944.	1.7	84
47	Retroviral-mediated expression of recombinant Fancc enhances the repopulating ability of Fanccâ^'/â^'hematopoietic stem cells and decreases the risk of clonal evolution. Blood, 2003, 101, 1299-1307.	0.6	75
48	Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. Journal of Clinical Investigation, 2012, 122, 3888-3899.	3.9	74
49	Posttransplantation Lymphoprolif erative Disorders in Bone Marrow Transplant Recipients Are Aggressive Diseases With a High Incidence of Adverse Histologic and Immunobiologic Features. American Journal of Clinical Pathology, 1997, 107, 419-429.	0.4	72
50	Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget, 2015, 6, 5615-5633.	0.8	72
51	Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease. Modern Pathology, 2013, 26, 204-212.	2.9	70
52	Bone Marrow Histopathology in Myeloproliferative Disordersâ€"Current Diagnostic Approach. Seminars in Hematology, 2005, 42, 184-195.	1.8	68
53	Association between Intracranial Plasmacytoma and Multiple Myeloma: Clinicopathological Outcome Study. Neurosurgery, 2001, 49, 1039-1045.	0.6	67
54	Fanconi anemia type C and p53 cooperate in apoptosis and tumorigenesis. Blood, 2003, 102, 4146-4152.	0.6	67

#	Article	IF	Citations
55	The Immune Response toHaemophilus ducreyiResembles a Delayedâ€Type Hypersensitivity Reaction throughout Experimental Infection of Human Subjects. Journal of Infectious Diseases, 1998, 178, 1688-1697.	1.9	66
56	Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. Neoplasia, 2018, 20, 574-593.	2.3	64
57	Lymphoblastic transformation of follicular lymphoma: a clinicopathologic and molecular analysis of 7 patients. Human Pathology, 2015, 46, 260-271.	1.1	63
58	Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. Haematologica, 2017, 102, 1352-1360.	1.7	62
59	Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study. Haematologica, 2014, 99, 821-829.	1.7	61
60	Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. Oncotarget, 2015, 6, 5597-5614.	0.8	61
61	Ex vivo culture of Fancc-/- stem/progenitor cells predisposes cells to undergo apoptosis, and surviving stem/progenitor cells display cytogenetic abnormalities and an increased risk of malignancy. Blood, 2005, 105, 3465-3471.	0.6	60
62	Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma. Clinical Cancer Research, 2014, 20, 5113-5123.	3.2	60
63	Rosaiâ€“Dorfman Disease Harboring an Activating KRAS K117N Missense Mutation. Head and Neck Pathology, 2016, 10, 394-399.	1.3	60
64	Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. Blood, 2016, 128, 3083-3100.	0.6	59
65	Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the <scp>EXTEND</scp> study. American Journal of Hematology, 2015, 90, 598-601.	2.0	58
66	Morphologic and immunohistochemical evaluation of splenic hematopoietic proliferations in neoplastic and benign disorders. Modern Pathology, 2005, 18, 1550-1561.	2.9	57
67	Myelodysplastic Syndromes. American Journal of Clinical Pathology, 2009, 132, 290-305.	0.4	55
68	Comparison of interleukin-11 and epidermal growth factor on residual small intestine after massive small bowel resection. Journal of Pediatric Surgery, 1998, 33, 24-29.	0.8	53
69	Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without) Tj ETQq1 1 0.784314 rgBT /Overlock 10 chronic myelomonocytic leukemia. Modern Pathology, 2017, 30, 1213-1222.	2.9	52
70	Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS). Oncotarget, 2010, 1, 483-496.	0.8	52
71	Hematopoietic precursor cells within the yolk sac tumor component are the source of secondary hematopoietic malignancies in patients with mediastinal germ cell tumors. Cancer, 1994, 73, 1535-1536.	2.0	51
72	CD34 immunohistochemistry of bone marrow biopsies: Prognostic significance in primary myelodysplastic syndromes. American Journal of Hematology, 1994, 46, 9-17.	2.0	51

#	Article	IF	Citations
73	Idiopathic Hypocomplementemic Interstitial Nephritis With Extensive Tubulointerstitial Deposits. American Journal of Kidney Diseases, 2001, 37, 388-399.	2.1	51
74	Therapy-Related Myeloid Neoplasms. American Journal of Clinical Pathology, 2009, 132, 410-425.	0.4	50
75	Genetic disruption of both Fancc and Fancg in mice recapitulates the hematopoietic manifestations of Fanconi anemia. Blood, 2010, 116, 2915-2920.	0.6	50
76	Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study. Modern Pathology, 2019, 32, 490-498.	2.9	50
77	Recombinant interferon-Î± in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response. Modern Pathology, 2015, 28, 1315-1323.	2.9	49
78	Continuous in vivo infusion of interferon-gamma (IFN-Î³) preferentially reduces myeloid progenitor numbers and enhances engraftment of syngeneic wild-type cells in Fancc-/- mice. Blood, 2004, 104, 1204-1209.	0.6	48
79	Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm. Leukemia Research, 2008, 32, 1931-1935.	0.4	48
80	Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Modern Pathology, 2015, 28, 1555-1573.	2.9	48
81	Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma. Clinical Cancer Research, 2016, 22, 3593-3605.	3.2	48
82	The effect of initial molecular profile on response to recombinant interferonâ€Î± (rIFNÎ±) treatment in early myelofibrosis. Cancer, 2017, 123, 2680-2687.	2.0	48
83	Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. Leukemia, 2017, 31, 625-636.	3.3	47
84	Tumor Proliferative Activity is Predictive of Pathological Stage in Clinical Stage a Nonseminomatous Testicular Germ Cell Tumors. Journal of Urology, 1996, 155, 579-586.	0.2	46
85	CD34 Immunostaining of Bone Marrow Biopsy Specimens Is a Reliable Way to Classify the Phases of Chronic Myeloid Leukemia. American Journal of Clinical Pathology, 1994, 101, 426-428.	0.4	44
86	Stromal SPARC contributes to the detrimental fibrotic changes associated with myeloproliferation whereas its deficiency favors myeloid cell expansion. Blood, 2012, 120, 3541-3554.	0.6	44
87	Immunohistochemistry Can Be Used to Subtype Acute Myeloid Leukemia in Routinely Processed Bone Marrow Biopsy Specimens. American Journal of Clinical Pathology, 2000, 113, 814-822.	0.4	43
88	Functional p85Î± gene is required for normal murine fetal erythropoiesis. Blood, 2003, 102, 142-145.	0.6	43
89	Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype. Cancer Immunology, Immunotherapy, 1992, 34, 241-251.	2.0	42
90	Myeloid Progenitor Cell Proliferation and Mobilization Effects of BB10010, a Genetically Engineered Variant of Human Macrophage Inflammatory Protein-1Î±, in a Phase I Clinical Trial in Patients with Relapsed/Refractory Breast Cancer. Blood Cells, Molecules, and Diseases, 1998, 24, 14-30.	0.6	42

#	Article	IF	Citations
91	The bone marrow stroma in hematological neoplasmsâ€"a guilty bystander. Nature Reviews Clinical Oncology, 2011, 8, 456-466.	12.5	42
92	Myeloid/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, or FGFR1 or With PCM1-JAK2. American Journal of Clinical Pathology, 2021, 155, 160-178.	0.4	42
93	Autologous Hematopoietic Stem-Cell Transplantation in Combination With Thalidomide As Treatment for Histiocytic Sarcoma: A Case Report and Review of the Literature. Journal of Clinical Oncology, 2011, 29, e251-e253.	0.8	41
94	Single nucleotide variation in the TP53 3â€² untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 121, 4529-4540.	0.6	41
95	Terminal Deoxynucleotidyl Transferase Staining in acute Leukemia and Normal Bone Marrow in Routinely Processed Paraffin Sections. American Journal of Clinical Pathology, 1994, 102, 640-645.	0.4	40
96	Flow Cytometric Immunophenotypic Characterization of Pediatric and Adult Minimally Differentiated Acute Myeloid Leukemia (AML-M0). American Journal of Clinical Pathology, 2000, 113, 193-200.	0.4	40
97	Reply to Matsui et al.. Leukemia, 2006, 20, 2042-2042.	3.3	40
98	Transformation of Follicular Lymphoma to Plasmablastic Lymphoma With c-mycGene Rearrangement. American Journal of Clinical Pathology, 2010, 134, 972-981.	0.4	40
99	Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia. Modern Pathology, 2013, 26, 751-761.	2.9	39
100	Evidence against KSHV infection in the pathogenesis of multiple myeloma. Virus Research, 1998, 57, 197-202.	1.1	37
101	Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities. Modern Pathology, 2012, 25, 65-74.	2.9	37
102	Myeloproliferative neoplasms with concurrent BCRâ€"ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group. Modern Pathology, 2018, 31, 690-704.	2.9	35
103	Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. Oncotarget, 2015, 6, 23157-23180.	0.8	35
104	Immunohistochemical assessment of tumor proliferation and volume of embryonal carcinoma identify patients with clinical stage a nonseminomatous testicular germ cell tumor at low risk for occult metastasis. Cancer, 1995, 75, 844-850.	2.0	34
105	Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents. British Journal of Haematology, 2011, 155, 248-255.	1.2	34
106	The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients. Journal of Cancer Research and Clinical Oncology, 2008, 134, 381-387.	1.2	33
107	A 2-Year, Longitudinal, Prospective Study of the Effects of Eltrombopag on Bone Marrow in Patients with Chronic Immune Thrombocytopenia. Acta Haematologica, 2017, 137, 66-72.	0.7	33
108	European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia. American Journal of Hematology, 2017, 92, 1062-1067.	2.0	33

#	Article	IF	Citations
109	Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary?. Oncotarget, 2015, 6, 13933-13945.	0.8	33
110	Flow cytometric analysis of normal and reactive spleen. Modern Pathology, 2004, 17, 918-927.	2.9	32
111	Prevalence and clinical implications of cyclin D1 expression in diffuse large Bâ€cell lymphoma (DLBCL) treated with immunochemotherapy: A report from the International DLBCL RituximabâCHOP Consortium Program. Cancer, 2014, 120, 1818-1829.	2.0	32
112	A Case of Chronic Neutrophilic Leukemia with Trisomy 8. Acta Haematologica, 1989, 81, 148-151.	0.7	30
113	Correlation Between Presence of Clonal Rearrangements of Immunoglobulin Heavy Chain Genes and B-Cell Antigen Expression in Hodgkinâ€™s Disease. American Journal of Clinical Pathology, 1995, 104, 413-418.	0.4	30
114	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With Trisomy 12 and Focal Cyclin D1 Expression: A Potential Diagnostic Pitfall. Archives of Pathology and Laboratory Medicine, 2005, 129, 92-95.	1.2	30
115	Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach. American Journal of Hematology, 2022, 97, 514-518.	2.0	30
116	Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage. Modern Pathology, 2013, 26, 1577-1585.	2.9	29
117	Phase I dose escalation study of lestaurtinib in patients with myelofibrosis. Leukemia and Lymphoma, 2015, 56, 2543-2551.	0.6	29
118	RelA NF-Î²B subunit activation as a therapeutic target in diffuse large B-cell lymphoma. Aging, 2016, 8, 3321-3340.	1.4	29
119	IgG4 plasma cell myeloma: new insights into the pathogenesis of IgG4-related disease. Modern Pathology, 2014, 27, 375-381.	2.9	28
120	Standards and impact of hematopathology in myelodysplastic syndromes (MDS). Oncotarget, 2010, 1, 483-96.	0.8	28
121	K-Ras is essential for normal fetal liver erythropoiesis. Blood, 2005, 105, 3538-3541.	0.6	27
122	Histiocytic cell neoplasms involving the bone marrow: summary of the workshop cases submitted to the 18th Meeting of the European Association for Haematopathology (EAHP) organized by the European Bone Marrow Working Group, Basel 2016. Annals of Hematology, 2018, 97, 2117-2128.	0.8	26
123	Comparison of therapyâ€related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study. American Journal of Hematology, 2020, 95, 799-808.	2.0	26
124	Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. Modern Pathology, 2019, 32, 1373-1385.	2.9	25
125	Selective purging by human interleukin-2 activated lymphocytes of bone marrows contaminated with a lymphoma line or autologous leukaemic cells. British Journal of Haematology, 1991, 78, 197-205.	1.2	24
126	Thrombotic Thrombocytopenic Purpura: Yesterday, Today, Tomorrow. Therapeutic Apheresis and Dialysis, 2004, 8, 80-86.	0.4	24

#	Article	IF	Citations
127	Bone Marrow Fibrosis and Diagnosis of Essential Thrombocythemia. Journal of Clinical Oncology, 2009, 27, e220-e221.	0.8	24
128	The detection of SRSF2 mutations in routinely processed bone marrow biopsies is useful in the diagnosis of chronic myelomonocytic leukemia. Human Pathology, 2014, 45, 2471-2479.	1.1	24
129	Mastocytosis and related disorders. Seminars in Diagnostic Pathology, 2012, 29, 19-30.	1.0	23
130	Splenic extramedullary hematopoietic proliferation in Philadelphia chromosome-negative myeloproliferative neoplasms: heterogeneous morphology and cytological composition. Modern Pathology, 2012, 25, 815-827.	2.9	23
131	Neutrophilic leukocytosis in advanced stage polycythemia vera: hematopathologic features and prognostic implications. Modern Pathology, 2015, 28, 1448-1457.	2.9	23
132	Primary Testicular and Paratesticular Lymphoma: A Retrospective Clinicopathologic Study of 34 Cases With Emphasis on Differential Diagnosis. Archives of Pathology and Laboratory Medicine, 2007, 131, 1040-1046.	1.2	23
133	De novo acute myeloid leukemia with 20â€“29% blasts is less aggressive than acute myeloid leukemia with â‰¥30% blasts in older adults: a <scp>B</scp>one <scp>M</scp>arrow <scp>P</scp>athology <scp>G</scp>roup study. American Journal of Hematology, 2014, 89, E193-9.	2.0	22
134	JAK2 V617Fâ€positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group. British Journal of Haematology, 2018, 182, 78-85.	1.2	22
135	Epstein-Barr virusâ€“positive nodular lymphocyte predominant Hodgkin lymphoma. Annals of Diagnostic Pathology, 2014, 18, 203-209.	0.6	21
136	Cyclin D1â€“Positive Diffuse Large B-Cell Lymphoma With IGH-CCND1 Translocation and BCL6 Rearrangement. American Journal of Clinical Pathology, 2015, 143, 288-299.	0.4	21
137	Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. Modern Pathology, 2015, 28, 1297-1314.	2.9	21
138	Impact of the 2016 revised WHO criteria for myeloproliferative neoplasms, unclassifiable: Comparison with the 2008 version. American Journal of Hematology, 2017, 92, E48-E51.	2.0	21
139	Concordance among hematopathologists in classifying blasts plus promonocytes: A bone marrow pathology group study. International Journal of Laboratory Hematology, 2020, 42, 418-422.	0.7	21
140	Myeloid/lymphoid neoplasms with FLT3 rearrangement. Modern Pathology, 2021, 34, 1673-1685.	2.9	21
141	Chronic idiopathic myelofibrosis: independent prognostic importance of bone marrow microvascular density evaluated by CD105 (endoglin) immunostaining. Modern Pathology, 2004, 17, 1513-1520.	2.9	20
142	Analysis of loss of heterozygosity and X chromosome inactivation in spleens with myeloproliferative disorders and acute myeloid leukemia. Modern Pathology, 2005, 18, 1562-1568.	2.9	20
143	Hypermethylation of the tumor suppressor gene PRDM1/Blimp-1 supports a pathogenetic role in EBV-positive Burkitt lymphoma. Blood Cancer Journal, 2014, 4, e261-e261.	2.8	20
144	Acute Myeloid Leukemia and Other Types of Disease Progression in Myeloproliferative Neoplasms. American Journal of Clinical Pathology, 2015, 144, 188-206.	0.4	20

#	Article	IF	Citations
145	The Spectrum of Aggressive Mastocytosis: A Workshop Report and Literature Review. Pathobiology, 2020, 87, 2-19.	1.9	20
146	Primary Hepatic B-Cell Lymphoma in a Child. American Journal of Surgical Pathology, 1993, 17, 1182-1186.	2.1	19
147	p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. Aging, 2016, 8, 345-365.	1.4	19
148	Inflammatory Pseudotumor of the Spleen in a 6-Year-Old Child: A Clinicopathologic Study. Archives of Pathology and Laboratory Medicine, 2003, 127, e127-e130.	1.2	19
149	Preliminary Studies on Melatonin in the Treatment of Myelodysplastic Syndromes Following Cancer Chemotherapy. Journal of Pineal Research, 1990, 8, 347-354.	3.4	18
150	Benign hematologic neoplasm associated with mediastinal mature teratoma in a patient with Klinefelter's syndrome: A case report. Medical and Pediatric Oncology, 1994, 23, 376-379.	1.0	18
151	Visceral leishmaniasis in a rheumatoid arthritis patient treated with methotrexate. International Journal of Infectious Diseases, 2009, 13, e169-e172.	1.5	18
152	Composite Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma Are Biclonal Lymphomas. American Journal of Clinical Pathology, 2012, 137, 647-659.	0.4	18
153	Myelodysplastic Syndrome, Unclassifiable (MDS-U) With 1% Blasts Is a Distinct Subgroup of MDS-U With a Poor Prognosis. American Journal of Clinical Pathology, 2017, 148, 49-57.	0.4	18
154	The myeloproliferative neoplasms, unclassifiable: clinical and pathological considerations. Modern Pathology, 2017, 30, 169-179.	2.9	18
155	Update on the pathologic diagnosis of chronic myelomonocytic leukemia. Modern Pathology, 2019, 32, 732-740.	2.9	18
156	The genetics of interdigitating dendritic cell sarcoma share some changes with Langerhans cell histiocytosis in select cases. Annals of Diagnostic Pathology, 2014, 18, 18-20.	0.6	17
157	Evaluation of NF-ÎºB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. Modern Pathology, 2015, 28, 1202-1213.	2.9	17
158	Bone marrow morphology and disease progression in congenital thrombocytopenia: a detailed clinicopathologic and genetic study of eight cases. Modern Pathology, 2017, 30, 486-498.	2.9	17
159	Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia. Modern Pathology, 2018, 31, 429-441.	2.9	17
160	Diffuse blastoid B-cell lymphoma: a histologically aggressive variant of t(14;18)-negative follicular lymphoma. Modern Pathology, 2009, 22, 1507-1517.	2.9	16
161	Myelodysplastic syndromes. Seminars in Diagnostic Pathology, 2011, 28, 258-272.	1.0	16
162	Impact of Bone Marrow Pathology on the Clinical Management of Philadelphia Chromosomeâ€“Negative Myeloproliferative Neoplasms. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 253-261.	0.2	16

#	Article	IF	Citations
163	Cytogenetic study in therapy-related myelodysplastic syndromes (t-MDS) and acute non-lymphocytic leukaemia (t-ANLL). British Journal of Cancer, 1990, 61, 425-428.	2.9	15
164	In VivoEffects of Recombinant Human Stem Cell Factor Treatment:A Morphologic and Immunohistochemical Study of Bone Marrow Biopsies. American Journal of Clinical Pathology, 1995, 103, 177-184.	0.4	15
165	Distinct morphophenotypic features of chronic Bâ€cell leukaemias identified with CDlc and CD23 antibodies. European Journal of Haematology, 1991, 47, 28-35.	1.1	15
166	European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012;97(3):360-5 - Comment. Haematologica, 2012, 97, e5-e6.	1.7	15
167	Advances in myelofibrosis: a clinical case approach. Haematologica, 2013, 98, 1499-1509.	1.7	15
168	Leptomeningeal relapse of multiple myeloma following allogeneic stem cell transplantation. Leukemia Research, 2002, 26, 689-692.	0.4	14
169	Bone marrow morphology predicts additional chromosomal abnormalities in patients with myelodysplastic syndrome with del(5q). Human Pathology, 2013, 44, 346-356.	1.1	14
170	A multimodality workâ€up of patients with Hypereosinophilia. American Journal of Hematology, 2018, 93, 1337-1346.	2.0	14
171	Difficulty distinguishing essential thrombocythaemia from polycythaemia vera in children with <scp>JAK</scp>2 V617Fâ€positive myeloproliferative neoplasms. British Journal of Haematology, 2019, 185, 136-139.	1.2	14
172	Myeloid neoplasms with isolated del(5q) and JAK2 V617F mutation: a â€œgrey zoneâ€•combination of myelodysplastic and myeloproliferative features?. Haematologica, 2020, 105, e276-e279.	1.7	14
173	Evaluation of Stroma in Human Immunodeficiency Virus/Acquired Immunodeficiency Syndromeâ€“Affected Bone Marrows and Correlation With CD4 Counts. Archives of Pathology and Laboratory Medicine, 2005, 129, 1137-1140.	1.2	14
174	Clonal X-chromosome inactivation suggests that splenic cord capillary hemangioma is a true neoplasm and not a subtype of splenic hamartoma. Modern Pathology, 2011, 24, 108-116.	2.9	13
175	Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders. American Journal of Clinical Pathology, 2021, 155, 179-210.	0.4	13
176	The stromal composition of mast cell aggregates in systemic mastocytosis. Modern Pathology, 2009, 22, 857-865.	2.9	12
177	Clinicopathologic evaluation of cytopenic patients with isolated trisomy 8: a detailed comparison between idiopathic cytopenia of unknown significance and low-grade myelodysplastic syndrome. Leukemia and Lymphoma, 2017, 58, 569-577.	0.6	12
178	Mastocytosis. American Journal of Clinical Pathology, 2021, 155, 239-266.	0.4	12
179	Reactive Eosinophil Proliferations in Tissue and the Lymphocytic Variant of Hypereosinophilic Syndrome. American Journal of Clinical Pathology, 2021, 155, 211-238.	0.4	12
180	Bone marrow fibrosis in chronic myelomonocytic leukemia is associated with increased megakaryopoiesis, splenomegaly and with a shorter median time to disease progression. Oncotarget, 2017, 8, 103274-103282.	0.8	12

#	Article	IF	Citations
181	Intraocular Inflammatory Myofibroblastic Tumor With ALK Overexpression. Archives of Pathology and Laboratory Medicine, 2004, 128, e5-e7.	1.2	12
182	Molecular Epidemiology of EBNA-1 Substrains of Epstein-Barr Virus in Posttransplant Lymphoproliferative Disorders Which Have Infrequent p53 Mutations. Leukemia and Lymphoma, 2000, 38, 563-576.	0.6	11
183	Ethnic and border differences on blood cancer presentation and outcomes: A Texas populationâ€based study. Cancer, 2021, 127, 1068-1079.	2.0	11
184	Mediastinal Non-seminomatous Germ Cell Tumours: Their Association with Non-germ Cell Malignancies. Pathology Research and Practice, 1999, 195, 589-594.	1.0	10
185	Inactivation of BANK1 in a novel IGH-associated translocation t(4;14)(q24;q32) suggests a tumor suppressor role in B-cell lymphoma. Blood Cancer Journal, 2014, 4, e215-e215.	2.8	10
186	Nuclear factor-erythroid 2, nerve growth factor receptor, and CD34â€“microvessel density are differentially expressed in primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Human Pathology, 2015, 46, 1217-1225.	1.1	10
187	â€Composite" lymphoma, lymphoplasmacytoid and diffuse large B-cell lymphoma of the spleen: molecular-genetic evidence of a common clonal origin. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1999, 435, 442-446.	1.4	9
188	Retroviral vector integration in post-transplant hematopoiesis in mice conditioned with either submyeloablative or ablative irradiation. Gene Therapy, 2009, 16, 1452-1464.	2.3	9
189	The effects of hematopoietic stem cell transplant on splenic extramedullary hematopoiesis in patients with myeloproliferative neoplasm-associated myelofibrosis. Hematology/ Oncology and Stem Cell Therapy, 2016, 9, 96-104.	0.6	9
190	How I investigate chronic myelomonocytic leukemia. International Journal of Laboratory Hematology, 2020, 42, 101-108.	0.7	9
191	Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1. Modern Pathology, 2021, 34, 20-31.	2.9	9
192	Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. Modern Pathology, 2021, , .	2.9	9
193	Acute Monoblastic Leukemia as a Second Malignancy Following Chemotherapy for Osteogenic Sarcoma: A Case Report. Pediatric Hematology and Oncology, 1988, 5, 39-46.	0.3	8
194	Primary Mediastinal Germ Cell Tumor Evolving Into an Extramedullary Acute Megakaryoblastic Leukemia Causing Cord Compression. Journal of Clinical Oncology, 2008, 26, 4686-4688.	0.8	8
195	Myeloid sarcoma with t(11;19)(q23;p13.3) (MLLâ€ELL) in the uterine cervix. British Journal of Haematology, 2011, 153, 679-679.	1.2	8
196	Evaluation of bone marrow morphology is essential for assessing disease status in recombinant interferon Î±-treated polycythemia vera patients. Haematologica, 2017, 102, e97-e99.	1.7	8
197	Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with increased blasts (<10%) or with other types of disease progression. Haematologica, 2020, 105, e221-e224.	1.7	8
198	Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group. Modern Pathology, 2021, 34, 1358-1366.	2.9	8

#	Article	IF	Citations
199	A Longitudinal Prospective Study Evaluating the Effects of Eltrombopag Treatment On Bone Marrow in Patients with Chronic Immune Thrombocytopenia: Interim Analysis At 1 Year.. Blood, 2012, 120, 2195-2195.	0.6	8
200	World Health Organization Classification of Myelodysplastic Syndromes. Current Pharmaceutical Design, 2012, 18, 3149-3162.	0.9	8
201	Pure Erythroid Leukemia Mimicking Ewing Sarcoma/Primitive Neuroectodermal Tumor in an Infant. Pediatric Blood and Cancer, 2016, 63, 935-937.	0.8	7
202	Evaluation of Bone Marrow Reticulin in Patients with Chronic Immune Thrombocytopenic Purpura (ITP) Treated with Eltrombopag â€“ Data From the EXTEND Study. Blood, 2011, 118, 528-528.	0.6	7
203	Morphologic, Immunologic, and Cytogenetic Characteristics of Secondary Acute Unclassifiable Leukemia in Hodgkin's Disease. Tumori, 1988, 74, 439-450.	0.6	6
204	Proliferating normal bone marrow cells do stain for Ki-67 antigen. British Journal of Haematology, 1993, 85, 835-836.	1.2	6
205	Most Myeloid Neoplasms With Deletion of Chromosome 16q Are Distinct From Acute Myeloid Leukemia With Inv(16)(p13.1q22). American Journal of Clinical Pathology, 2017, 147, 411-419.	0.4	6
206	Trends in Bone Marrow Sampling and Core Biopsy Specimen Adequacy in the United States and Canada. American Journal of Clinical Pathology, 2018, 150, 393-405.	0.4	6
207	Chronic lymphocytic leukemia with TP53 gene alterations: a detailed clinicopathologic analysis. Modern Pathology, 2020, 33, 344-353.	2.9	6
208	Local Delivery of Nadroparin via Hydrogel-coated Angioplasty Balloon: Effect on Platelet Deposition and Smooth Muscle Cell Proliferationâ€"An Experimental Study. Journal of Vascular and Interventional Radiology, 2000, 11, 115-122.	0.2	5
209	CD4-Negative Variant of Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm With a Novel PBRM1 Mutation in an 11-Year-Old Girl. American Journal of Clinical Pathology, 2017, 147, 453-460.	0.4	5
210	Recombinant Interferon Alpha (rIFN) May Retard Progression Of Early Myelofibrosis By Reducing Splenomegaly and By Decreasing Marrow Fibrosis. Blood, 2013, 122, 4053-4053.	0.6	5
211	Mast cell sarcoma: 2 Mayo Clinic cases. American Journal of Hematology, 2022, 97, 1381-1383.	2.0	5
212	A 51-Year-Old Female With Nephrotic Syndrome, Renal Failure, and Hepatitis C Virus Infection. American Journal of Kidney Diseases, 2001, 37, 442-447.	2.1	4
213	Loss of heterozygosity identifies genetic changes in chronic myeloid disorders, including myeloproliferative disorders, myelodysplastic syndromes and chronic myelomonocytic leukemia. Modern Pathology, 2007, 20, 1166-1171.	2.9	4
214	Acute aleukemic mast cell leukemia: Report of a case and review of the literature. Leukemia Research Reports, 2020, 14, 100230.	0.2	4
215	Terminal deoxynucleotidyl transferase-positive cells in spleen, appendix and branchial cleft cysts in pediatric patients. Haematologica, 2006, 91, 1139-40.	1.7	4
216	A reevaluation of erythroid predominance in Acute Myeloid Leukemia using the updated WHO 2016 Criteria. Modern Pathology, 2018, 31, 873-880.	2.9	3

#	Article	IF	Citations
217	A lucky mistake: the splenic glands of Marcello Malpighi. Human Pathology, 2018, 72, 191-195.	1.1	3
218	Challenges in Diagnosing Myelodysplastic Syndromes in the Era of Genetic Testing: Proceedings of the 13th Workshop of the European Bone Marrow Working Group. Pathobiology, 2019, 86, 62-75.	1.9	3
219	Comments on preâ€fibrotic myelofibrosis and how should it be managed. British Journal of Haematology, 2019, 186, 358-360.	1.2	3
220	B-cell neoplasms and Hodgkin lymphoma in the spleen. Seminars in Diagnostic Pathology, 2021, 38, 125-134.	1.0	3
221	The t(14;18)(q32;q21) Characterizes a Subset of Patients with Diffuse Large-B Cell Lymphoma of Germinal Center Origin with Poor Outcome: Report From the International DLBCL Rituximab-CHOP Consortium Program Study. Blood, 2011, 118, 949-949.	0.6	3
222	Radiation Therapy Significantly Improves Survival Of Patients With Diffuse Large B-Cell Lymphoma Associated With MYC Translocation: A Report From The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 122, 641-641.	0.6	3
223	The Effect of Initial Molecular Profile on Response to Recombinant Interferon Alpha (rIFNÎ±) Treatment in Early Myelofibrosis. Blood, 2016, 128, 944-944.	0.6	3
224	How I Diagnose Primary Myelofibrosis. American Journal of Clinical Pathology, 2022, 157, 518-530.	0.4	3
225	Platelet Depletion During Pediatric Peripheral Blood Progenitor Cell (PBPC) Harvesting. Transfusion Science, 1998, 19, 61.	0.6	2
226	GATA1 downregulation in prefibrotic and fibrotic stages of primary myelofibrosis and in the myelofibrotic progression of other myeloproliferative neoplasms. Leukemia Research, 2021, 100, 106495.	0.4	2
227	Progression, transformation, and unusual manifestations of myelodysplastic syndromes and myelodysplastic-myeloproliferative neoplasms: lessons learned from the XIV European Bone Marrow Working Group Course 2019. Annals of Hematology, 2021, 100, 117-133.	0.8	2
228	Antibodies and Immunohistochemical Evaluation for the Diagnosis of Hematological Malignancies. Methods in Molecular Biology, 2007, 378, 91-123.	0.4	2
229	Prospective Evaluation of the World Health Organization Criteria for the Diagnosis of Polycythemia Vera,. Blood, 2011, 118, 3837-3837.	0.6	2
230	EAHP 2020 workshop proceedings, pediatric myeloid neoplasms. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 621-646.	1.4	2
231	The normal bone marrow and an approach to bone marrow evaluation of neoplastic and proliferative processes. , 2006, , 5-15.		1
232	Mutational Profile and Prognostic Significance of TP53 in Diffuse Large B-cell Lymphoma Patients Treated with Rituximab-CHOP: A Report From an International DLBCL Rituximab-CHOP Consortium Program Study. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, S382.	0.2	1
233	Immune thrombocytopenia is associated with persistently deranged fibrosis-related seromarker profiles but low bone marrow fibrosis grades: A 2-year observational study on thrombopoietin receptor agonist treatment. Platelets, 2019, 30, 222-228.	1.1	1
234	Myelodysplastic/myeloproliferative neoplasms: are morphology and immunophenotyping still relevant?. Best Practice and Research in Clinical Haematology, 2020, 33, 101139.	0.7	1

#	Article	IF	Citations
235	The Bone Marrow Biopsy. , 2020, , 1-13.		1
236	Update on the classification of myeloid neoplasms: The 2016 revised World Health Organization classification of hematopoietic and lymphoid neoplasms. Advances in Cell and Gene Therapy, 2020, 3, e78.	0.6	1
237	Primary pancreatic diffuse large Bâ€cell lymphoma, activated Bâ€cell subtype, diagnosed by endoscopic ultrasoundâ€guided fine needle aspirationâ€"A case report and review of the literature. Clinical Case Reports (discontinued), 2021, 9, 669-672.	0.2	1
238	Pathology of the spleen: INTRODUCTION. Seminars in Diagnostic Pathology, 2021, 38, 111.	1.0	1
239	Results from the Myeloproliferative Neoplasm Patient Care Survey: Patient Care Opportunities and Challenges. Blood, 2018, 132, 4289-4289.	0.6	1
240	Clinical Impact of TP53 Gene Mutations in Diffuse Large B-Cell Lymphoma (DLBCL): An International DLBCL Rituxan-CHOP Consortium Program Study.. Blood, 2009, 114, 967-967.	0.6	1
241	Characterization of Splenic CD34+ Cells From Patients with Primary Myelofibrosis. Blood, 2011, 118, 2810-2810.	0.6	1
242	Prognostic Significance and Phenotypic Manifestations of MYC/BCL2 Protein Expression in Diffuse Large B-Cell Lymphoma (DLBCL) with Extranodal Organ Involvement: A Report of the International DLBCL Rituximab-CHOP Consortium Program Study. Blood, 2012, 120, 544-544.	0.6	1
243	Inactivation Of BANK1 By a Novel IGH-Associated Translocation and 5â€™ Hypermethylation In B-Cell Lymphomas. Blood, 2013, 122, 2497-2497.	0.6	1
244	Evaluation Of The Effects Of Long-Term Treatment With Eltrombopag On Bone Marrow In Patients With Chronic Immune Thrombocytopenia (ITP) â€" Data From The EXTEND Study. Blood, 2013, 122, 326-326.	0.6	1
245	Bone Marrow Core Biopsy Adequacy and Variability in the United Stated and Canada: A Multicenter Retrospective Study. Blood, 2014, 124, 1316-1316.	0.6	1
246	STAT3 Expression and Clinical Implications In De Novo Diffuse Large B-Cell Lymphoma: A Report From The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 122, 365-365.	0.6	1
247	Bone Marrow Fibrosis In Immune Thrombocytopenia (ITP) Patients Treated With Thrombopoietin Receptor Agonists (TRA) â€" a Single Center Long-Term Follow-Up. Blood, 2013, 122, 3527-3527.	0.6	1
248	Akt Activation Confers an Inferior Survival in Patients with Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program. Blood, 2014, 124, 143-143.	0.6	1
249	Of drills and bones: Giovanni Ghedini and the origin of bone marrow biopsy. British Journal of Haematology, 2022, , .	1.2	1
250	Platelet loss during peripheral blood progenitor cell collections. Transfusion Science, 1996, 17, 475.	0.6	0
251	Biological Determinants of Long-Term Survival in Chronic Myelogenous Leukemia Patients Treated with Conventional Chemotherapy. Acta Haematologica, 1997, 97, 187-188.	0.7	0
252	Mesocaval shunt inhibits primary and metastatic hepatoma growth and enhances apoptosis. Journal of Pediatric Surgery, 1998, 33, 1128-1133.	0.8	0

#	Article	IF	Citations
253	Granulomatous and histiocytic disorders. , 2006, , 16-21.		0
254	Chronic myeloproliferative disorders and systemic mastocytosis. , 2006, , 73-87.		0
255	The aplasias. , 0, , 22-30.		0
256	Acute leukemia. , 2006, , 58-72.		0
257	F.101. Acquired Hemolytic Anemia in an Infant After Small Bowel Transplantation. Clinical Immunology, 2008, 127, S76.	1.4	0
258	Aberrantly sustained PAX5 expression in plasma cell differentiation is a frequent feature in lymphoplasmacytic lymphoma but not marginal zone lymphoma in bone marrow. Journal of Hematopathology, 2013, 6, 169-177.	0.2	0
259	Diffuse variant of lymphocyte-predominant Hodgkin lymphoma: a diagnostic challenge. Journal of Hematopathology, 2013, 6, 145-150.	0.2	0
260	Clinical and Biological significance of MYC/BCL6 dual gene rearrangements and protein co-expression in de novo diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S228.	0.2	0
261	MYC Signatures and Characterization of MYC-Driven Aggressive B-Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S223.	0.2	0
262	A rare case of acute myeloid leukemia with der(1)t(1;19)(p13;p13.1). Leukemia Research Reports, 2019, 12, 100175.	0.2	0
263	Recent Advancements in Hematology: Knowledge, Methods and Dissemination. Hemato, 2020, 1, 5-6.	0.2	0
264	Lymph Nodes. , 2022, , 763-813.		0
265	Protein Profiling in Childhood Precursor B Acute Lymphoblastic Leukemia using Surface Enhanced Laser Desorption/Ionization (SELDI) Mass Spectrometry: A Study of Archival Samples.. Blood, 2004, 104, 1086-1086.	0.6	0
266	A Model of Clonal Evolution and Myelodysplasia (MDS) on Mice with Genetic Disruption of Both Fancc and Fancg.. Blood, 2006, 108, 2627-2627.	0.6	0
267	Loss of Heterozygosity in Bone Marrows of Patients with Iron-Deficiency Anemia.. Blood, 2006, 108, 4863-4863.	0.6	0
268	Overexpression of NF-E2 In Vivo Causes Thrombocytosis and Acute Leukemia: A Murine Model of Myeloproliferative Neoplasms.. Blood, 2009, 114, 961-961.	0.6	0
269	Promoter and Exon 1 Hypermethylation of the Tumor Suppressor Gene PRDM1/Blimp-1 indicates Its Pathogenetic Role in EBV-Positive Burkitt Lymphoma,. Blood, 2011, 118, 3471-3471.	0.6	0
270	Clinicopathologic Characterization of Acute Myeloid Leukemia and Myelodysplastic Syndrome with Inv(3)(q21q26.2)/t(3;3)(q21;q26.2) Reveals That Complex Karyotype but Not Blast Percentage Is Associated with Poor Survival; A Bone Marrow Pathology Group Study. Blood, 2012, 120, 3847-3847.	0.6	0

#	Article	IF	Citations
271	MYC Mutation Profiling In 708 De Novo Diffuse Large B-Cell Lymphoma Demonstrates That Genetic Abnormalities In The Coding Sequence and Untranslated Regions Have Different Prognostic and Clinical Significance: A Report From The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 122, 363-363.	0.6	0
272	Radiation Therapy Significantly Improves Survival Of Patients With Diffuse Large B-Cell Lymphoma Associated With MYC Translocation: A Report From The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 122, 213-213.	0.6	0
273	NF-Î²B Subunit c-Rel Cooperates with Myc and Mutated p53 to Confer Significantly Worse Survival in Patients with Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program. Blood, 2014, 124, 1620-1620.	0.6	0
274	Evaluation of Bone Marrowmmorphology in Addition to JAK2 Allele Burden Is Essential for Assessing Disease Status in Recombinant Interferon Alpha-Treated Polycythemia Vera Patients. Blood, 2016, 128, 5471-5471.	0.6	0
275	Myelodysplastic Syndromes (MDS). Encyclopedia of Pathology, 2018, , 1-12.	0.0	0
276	Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN). Encyclopedia of Pathology, 2018, , 1-10.	0.0	0
277	Clinical, Immunophenotypic and Genomic Findings of Acute Undifferentiated Leukemia and Comparison to AML with Minimal Differentiation: A Study from the Bone Marrow Pathology Group. Blood, 2018, 132, 1491-1491.	0.6	0
278	Myelodysplastic Syndromes (MDS). Encyclopedia of Pathology, 2020, , 358-369.	0.0	0
279	Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN). Encyclopedia of Pathology, 2020, , 369-378.	0.0	0
280	Retrospective Study of Incidence and Survival for Patients with Hematologic Malignancies Residing at the U.S./Mexico Border. Blood, 2019, 134, 4782-4782.	0.6	0
281	Addressing the Challenges of Eosinophilia and Mastocytosis. American Journal of Clinical Pathology, 2021, 155, 156-159.	0.4	0
282	Discordant PET Findings and a High Relapse Rate Characterize Hispanics With Hodgkinâ€™s Lymphoma Treated With ABVD. Cancer Diagnosis & Prognosis, 2021, 1, 127-133.	0.3	0
283	Post-operative hyperleukocytosis and leukostasis as the initial presentation of chronic myelomonocytic leukemia: a case report and review of literature.. Leukemia Research Reports, 2021, 16, 100283.	0.2	0
284	Immunohistochemistry and Flow Cytometry in Bone Marrow Haematopathology. , 2020, , 340-361.		0
285	Myeloproliferative Neoplasms. , 2020, , 146-161.		0
286	Mature Lymphoid Neoplasms. , 2020, , 245-282.		0
287	Hyperplasia. , 2020, , 64-78.		0
288	Acute Myeloid Leukaemia. , 2020, , 127-145.		0

#	Article	IF	Citations
289	Infective, Granulomatous and Benign Histiocytic Disorders. , 2020, , 79-97.		0
290	Myelodysplastic/Myeloproliferative Neoplasms. , 2020, , 162-180.		0
291	Myeloid and Lymphoid Neoplasms Associated with Eosinophilia. , 2020, , 200-230.		0